Je was op zoek naar: mkrr (Sloveens - Engels)

v ključni študiji iii. faze pri bolnikih mkrr niso zabeležili primerov pres.
pres was not reported in the pivotal phase iii study of mcrc patients.

preglednica 1- neželeni učinki opisani pri prejemnikih sheme zaltrap/folfiri v študiji mkrr
table 1 - adverse reactions reported in patients treated with the zaltrap/folfiri regimen from the mcrc study

pri bolnikih z zmogljivostnim stanjem 2 po ecog je pred uvedbo zdravila vectibix v kombinaciji s kemoterapijo za zdravljenje mkrr priporočljivo oceniti koristi in tveganje.
for patients with ecog 2 performance status, assessment of benefit-risk is recommended prior to initiation of vectibix in combination with chemotherapy for treatment of mcrc.

zdravilo vectibix v kombinaciji s kemoterapijo na podlagi oksaliplatina pri bolnikih z mkrr z mutantnim ras oz. bolnikih z mkrr, pri katerih stanje ras tumorja ni znano
vectibix in combination with oxaliplatin-based chemotherapy in patients with mutant ras mcrc or for whom ras tumour status is unknown

kombinacija zdravila vectibix s kemoterapijo, ki vključuje oksaliplatin, je kontraindicirana pri bolnikih z mkrr z mutantnim ras ali pri katerih stanje ras ni znano.
the combination of vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant ras mcrc or for whom ras mcrc status is unknown.

opravljena je bila vnaprej opredeljena retrospektivna analiza podskupine 641 od 656 bolnikov z mkrr z divjim tipom kras (ekson 2).
a predefined retrospective subset analysis of 641 patients of the 656 patients with wild-type kras (exon 2) mcrc was performed.

kombinacija zdravila vectibix in kemoterapije, ki vključuje oksaliplatin, je kontraindicirana pri bolnikih z mkrr z mutantnim ras in tistih bolnikih z mkrr, pri katerih stanje ras ni znano (glejte poglavje 4.4).
the combination of vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant ras mcrc or for whom ras mcrc status is unknown (see section 4.4).